8.1K
Articles
237.5K
Citations
3.1
avg. Impact Factor
199
h-index

Most Cited Articles of Division of Hematology in 2014

TitleJournalYearCitations
International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaLancet Oncology, The20142.3K
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia2014880
Intervention to promote physician well-being, job satisfaction, and professionalism: a randomized clinical trialJAMA Internal Medicine2014434
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisBlood2014424
IMWG consensus on risk stratification in multiple myelomaLeukemia2014387
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsLeukemia2014381
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesBlood2014294
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationJournal of Clinical Oncology2014255
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinomaPLoS Genetics2014239
Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patientsMayo Clinic Proceedings2014234
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerJournal of the National Cancer Institute2014215
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patientsLeukemia2014213
Left ventricular amyloid deposition in patients with heart failure and preserved ejection fractionJACC: Heart Failure2014212
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patientsLeukemia2014211
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyLancet Oncology, The2014207
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaBlood2014202
Remission of disseminated cancer after systemic oncolytic virotherapyMayo Clinic Proceedings2014202
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectJournal of the National Cancer Institute Monographs2014199
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsLeukemia2014186
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesLeukemia2014184
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseasesLeukemia2014179
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Leukemia2014179
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinomaHuman Pathology2014179
Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosisMayo Clinic Proceedings2014173
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaBlood2014169